https://www.businesswire.com/news/home/20230103005162/en/Newly-Published-Retrospective-Analysis-Showed-Lower-All-Cause-Mortality-Risk-Among-Parkinson%E2%80%99s-Disease-Psychosis-Patients-Treated-with-NUPLAZID%C2%AE-pimavanserin-Compared-to-Those-Treated-with-Other-Atypical-Antipsychotics
0
0
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson's Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics - Business Wire
1/3/23 at 2:00pm
Organization
Business Wire
Authors
Details
51 words
Summarize
Mental Health Health Neurological Conditions Drugs & Medications Retrospective Analysis NUPLAZID Parkinson's Disease Psychosis Patients Drug Safety BUSINESS WIRE Acadia Pharmaceuticals Inc Nasdaq
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lowe
Create an account or login to join the discussion